149 related articles for article (PubMed ID: 7923693)
1. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis.
Tanaka A; Matsumori A; Wang W; Sasayama S
Circulation; 1994 Oct; 90(4):2051-5. PubMed ID: 7923693
[TBL] [Abstract][Full Text] [Related]
2. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
Kito G; Morimoto S; Shiomi M
Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus.
Araki M; Kanda T; Imai S; Suzuki T; Murata K; Kobayashi I
J Cardiovasc Pharmacol; 1995 Jul; 26(1):61-5. PubMed ID: 7564367
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
6. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice.
Yamamoto K; Shioi T; Uchiyama K; Miyamoto T; Sasayama S; Matsumori A
J Am Coll Cardiol; 2003 Dec; 42(11):2000-6. PubMed ID: 14662266
[TBL] [Abstract][Full Text] [Related]
7. Contribution of endothelin-1 to myocardial injury in a murine model of myocarditis: acute effects of bosentan, an endothelin receptor antagonist.
Ono K; Matsumori A; Shioi T; Furukawa Y; Sasayama S
Circulation; 1999 Oct; 100(17):1823-9. PubMed ID: 10534471
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
Kito G; Ito K; Shiomi M
Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
Matsumori A; Sasayama S
Eur Heart J; 1995 Dec; 16 Suppl O():140-3. PubMed ID: 8682082
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor antagonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril.
Furukawa Y; Matsumori A; Hirozane T; Sasayama S
Circulation; 1996 Jan; 93(2):333-9. PubMed ID: 8548907
[TBL] [Abstract][Full Text] [Related]
11. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin.
Yu F; Chen R; Takahashi T; Sumino H; Morimoto S; Nakahashi T; Iwai K; Matsumoto M; Kanda T
Int J Cardiol; 2008 Oct; 129(3):414-21. PubMed ID: 18053594
[TBL] [Abstract][Full Text] [Related]
12. Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice.
Baba T; Kanda T; Kobayashi I
Life Sci; 2000 Jun; 67(5):587-97. PubMed ID: 10993124
[TBL] [Abstract][Full Text] [Related]
13. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog.
Miyazaki M; Shiota N; Sakonjo H; Takai S
Jpn J Pharmacol; 1999 Apr; 79(4):455-60. PubMed ID: 10361885
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury.
Yoshiyama M; Kim S; Yamagishi H; Omura T; Tani T; Yanagi S; Toda I; Teragaki M; Akioka K; Takeuchi K
Am Heart J; 1994 Jul; 128(1):1-6. PubMed ID: 8017262
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus.
Yamada T; Matsumori A; Sasayama S
Circulation; 1994 Feb; 89(2):846-51. PubMed ID: 8313574
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
Kojima M; Shiojima I; Yamazaki T; Komuro I; Zou Z; Wang Y; Mizuno T; Ueki K; Tobe K; Kadowaki T
Circulation; 1994 May; 89(5):2204-11. PubMed ID: 8181146
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression.
Saegusa S; Fei Y; Takahashi T; Sumino H; Moriya J; Kawaura K; Yamakawa J; Itoh T; Morimoto S; Nakahashi T; Iwai K; Matsumoto M; Kanda T
Cardiovasc Drugs Ther; 2007 Jun; 21(3):155-60. PubMed ID: 17484035
[TBL] [Abstract][Full Text] [Related]
19. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats.
Kawamura M; Terashita Z; Okuda H; Imura Y; Shino A; Nakao M; Nishikawa K
J Pharmacol Exp Ther; 1993 Sep; 266(3):1664-9. PubMed ID: 8371164
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats.
Kim S; Ohta K; Hamaguchi A; Omura T; Yukimura T; Miura K; Inada Y; Ishimura Y; Chatani F; Iwao H
J Pharmacol Exp Ther; 1995 Apr; 273(1):509-15. PubMed ID: 7714806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
